Viral pathogens in bone- and bone-marrow derived malignancies: Friends or foes?

IF 13.8 2区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Molecular Aspects of Medicine Pub Date : 2025-12-01 Epub Date: 2025-11-24 DOI:10.1016/j.mam.2025.101427

Pei Liu , Weiwei Wang , Kun Zhao , Hong Zhang , Mingqiang Liu , Jianlei Li , Yadong Guo , Anquan Shang , Yongqiang Sun

{"title":"Viral pathogens in bone- and bone-marrow derived malignancies: Friends or foes?","authors":"Pei Liu , Weiwei Wang , Kun Zhao , Hong Zhang , Mingqiang Liu , Jianlei Li , Yadong Guo , Anquan Shang , Yongqiang Sun","doi":"10.1016/j.mam.2025.101427","DOIUrl":null,"url":null,"abstract":"<div><h3>Bone</h3><div>and bone-marrow associated cancers, including osteosarcoma, Ewing sarcoma, multiple myeloma, and various leukemias, are highly aggressive tumors with limited therapeutic options and poor outcomes. Viruses play a paradoxical role in these diseases, acting both as pathogenic drivers and as potential therapeutic agents. On one hand, oncogenic viruses such as Epstein–Barr virus (EBV), human T-cell leukemia virus type 1 (HTLV-1), and hepatitis viruses have been implicated in the initiation and progression of certain hematologic and skeletal malignancies. On the other hand, oncolytic viruses have emerged as promising ‘friends,’ engineered to selectively infect, lyse, and stimulate immune responses against malignant cells within the unique microenvironment of bone and bone marrow. This duality raises critical questions about how viral biology intersects with cancer pathogenesis and therapy. In this review, we explore the evidence for viral pathogens as both foes that contribute to tumorigenesis and friends that can be harnessed as novel therapeutic platforms. We further highlight delivery challenges, safety considerations, and translational opportunities that may shape the future of virotherapy for bone and marrow cancers.</div></div>","PeriodicalId":49798,"journal":{"name":"Molecular Aspects of Medicine","volume":"106 ","pages":"Article 101427"},"PeriodicalIF":13.8000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Aspects of Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0098299725000913","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Bone

and bone-marrow associated cancers, including osteosarcoma, Ewing sarcoma, multiple myeloma, and various leukemias, are highly aggressive tumors with limited therapeutic options and poor outcomes. Viruses play a paradoxical role in these diseases, acting both as pathogenic drivers and as potential therapeutic agents. On one hand, oncogenic viruses such as Epstein–Barr virus (EBV), human T-cell leukemia virus type 1 (HTLV-1), and hepatitis viruses have been implicated in the initiation and progression of certain hematologic and skeletal malignancies. On the other hand, oncolytic viruses have emerged as promising ‘friends,’ engineered to selectively infect, lyse, and stimulate immune responses against malignant cells within the unique microenvironment of bone and bone marrow. This duality raises critical questions about how viral biology intersects with cancer pathogenesis and therapy. In this review, we explore the evidence for viral pathogens as both foes that contribute to tumorigenesis and friends that can be harnessed as novel therapeutic platforms. We further highlight delivery challenges, safety considerations, and translational opportunities that may shape the future of virotherapy for bone and marrow cancers.

查看原文本刊更多论文

骨髓源性恶性肿瘤中的病毒病原体：是敌是友？

骨和骨髓相关癌症，包括骨肉瘤、尤文氏肉瘤、多发性骨髓瘤和各种白血病，是高度侵袭性的肿瘤，治疗选择有限，预后差。病毒在这些疾病中扮演着矛盾的角色，既是致病驱动因素，又是潜在的治疗剂。一方面，eb病毒（EBV）、1型人t细胞白血病病毒（HTLV-1）和肝炎病毒等致癌病毒与某些血液学和骨骼恶性肿瘤的发生和发展有关。另一方面，溶瘤病毒已经成为很有前途的“朋友”，被设计成在骨骼和骨髓的独特微环境中选择性地感染、溶解和刺激针对恶性细胞的免疫反应。这种两重性提出了关于病毒生物学如何与癌症发病机制和治疗交叉的关键问题。在这篇综述中，我们探讨了病毒病原体作为促进肿瘤发生的敌人和可以作为新的治疗平台的朋友的证据。我们进一步强调了可能塑造未来骨髓癌病毒治疗的递送挑战、安全性考虑和转化机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Aspects of Medicine 医学-生化与分子生物学

CiteScore

18.20

自引率

0.00%

发文量

审稿时长

55 days

期刊介绍： Molecular Aspects of Medicine is a review journal that serves as an official publication of the International Union of Biochemistry and Molecular Biology. It caters to physicians and biomedical scientists and aims to bridge the gap between these two fields. The journal encourages practicing clinical scientists to contribute by providing extended reviews on the molecular aspects of a specific medical field. These articles are written in a way that appeals to both doctors who may struggle with basic science and basic scientists who may have limited awareness of clinical practice issues. The journal covers a wide range of medical topics to showcase the molecular insights gained from basic science and highlight the challenging problems that medicine presents to the scientific community.